Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diamyd Medical ABFRA:DMN -3.97%41 PB Ratio is 0.47 as of Aug. 10, 2026, which is 93% below its 10-year median of 6.88. GuruFocus rates FRA:DMN with a GF Score™ of 41/100 and a GF Value™ of €0.07 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,223 Biotechnology companies, Diamyd Medical AB ranks better than 92.4% on this metric.
Diamyd Medical AB stock PB Ratio (=0.6) is close to 10-year low of 0.6.
The historical rank and industry rank for Diamyd Medical AB's PB Ratio or its related term are showing as below:
FRA:DMN'
s PB Ratio Range Over the Past 10 Years
Min: 0.6 Med: 6.88 Max: 65.11
Current: 0.6
During the past 13 years, Diamyd Medical AB's highest PB Ratio was 65.11. The lowest was 0.60. And the median was 6.88.
FRA:DMN's PB Ratio is ranked better than 92.4% of 1223
companies
in the Biotechnology industry
Industry Median: 2.94
vs FRA:DMN: 0.60
During the past 12 months, Diamyd Medical AB's average Book Value Per Share Growth Rate was -29.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -9.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 8.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Diamyd Medical AB was 51.30% per year. The lowest was -46.30% per year. And the median was -12.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Diamyd Medical AB PB Ratio Related Terms
Diamyd Medical AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Diamyd Medical AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Diamyd Medical AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Diamyd Medical AB (FRA:DMN) has a PB Ratio of 0.47 as of Aug. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Diamyd Medical AB and its competitors. This is 93% below median its historical median of 6.88. Over the past decade, Diamyd Medical AB's PB Ratio has ranged from 0.60 to 65.11. According to the industry distribution chart, Diamyd Medical AB ranks #93 out of 1223 companies in the Biotechnology industry, placing it in the top 7.6%.
Is Diamyd Medical AB's PB Ratio too high?
Diamyd Medical AB's current PB Ratio of 0.47 is 93% below median its 10-year median of 6.88. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 65.11. The Biotechnology industry median PB Ratio is 2.94. Diamyd Medical AB's value of 0.47 is 84% below this industry median. Based on the distribution chart, Diamyd Medical AB ranks #93 out of 1223 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Diamyd Medical AB has a GF Score™ of 41/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #93 out of 1223 companies for PB Ratio. This places Diamyd Medical AB in the top 8% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.94. Diamyd Medical AB's value of 0.47 is 84% below this benchmark. Historically, Diamyd Medical AB's own PB Ratio has ranged from 0.60 to 65.11 over the past decade. While the company's 10-year median is 6.88 vs. the industry median of 2.94, Diamyd Medical AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.94, based on 1,223 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diamyd Medical AB's current PB Ratio of 0.47 is 84% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Diamyd Medical AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamyd Medical AB's current PB Ratio is 0.47, which is 93% below median its own 10-year median of 6.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (FRA:DMN) is currently considered Fairly Valued. The stock's GF Value™ is €0.07, compared to a current price of €0.07 — trading 3.6% above its estimated fair value. The current PB Ratio is 0.47, which is 93% below median its 10-year median of 6.88 and 84% below the Biotechnology industry median of 2.94. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Diamyd Medical AB (FRA:DMN), the current PB Ratio is 0.47 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be overvalued.
The current stock price of €0.07 is trading 3.6% above its estimated GF Value™ of €0.07.
GuruFocus considers Diamyd Medical AB to be Fairly Valued.
Key valuation signals for FRA:DMN:
PB Ratio: 0.47 (93% below median its 10-year median of 6.88)
GF Value™: €0.07 vs. price of €0.07 (3.6% above fair value)
Industry Position: 84% below the Biotechnology median (#93 of 1223)
No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score
Get the complete analysis for FRA:DMN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DMN has been successfully added to your 
